Charles Chau

Charles Chau

Education

University of Hong Kong (LL.B., 1997)
University of Hong Kong (P.C.L.L., 1998)
University of Cambridge (LL.M., 1999)

Bar Admissions

Hong Kong (Solicitor)

Charles Chau is a partner in Morrison & Foerster’s Hong Kong office. He focuses in providing advice on mergers and acquisitions, listings and public offerings, capital markets transactions, securities regulatory compliance, joint ventures, and other commercial transactions across Hong Kong, mainland China, and the Asia-Pacific region.

Mr. Chau has extensive experience across a wide variety of industry sectors, including banking and financial services, health care, biotech, retail, real estate, and manufacturing. Over the years, Mr. Chau has represented clients in more than 100 public and private company acquisitions, joint ventures, financings, and pre-IPO investment, including acting for China CNR Corporation Limited in its US$26 billion merger with CSR Corporation Limited, being the first merger of two companies listed in both Hong Kong and Shanghai. He has also represented Chinese companies on their outbound acquisitions in the United States.  On the capital markets side, Mr. Chau has worked on many IPOs and securities placement transactions. Representative matters include the IPOs of Sinopharm Group, China CNR Corporation, Guodian Technology and Environment Group Corporation Limited, as well as the A+H rights issue of China CITIC Bank.

Mr. Chau has been named as a leading practitioner for Equity Capital Markets by Chambers Asia Pacific 2016, as well as a recommended practitioner for Equity Capital Markets in Hong Kong and Real Estate in China by Legal 500 Asia Pacific 2016.

Mr. Chau holds offices in various public bodies, including serving as an Adjudicator of the Registration of Persons Tribunal and a committee member of the Legal Committee and the Young Executive Club of the Hong Kong General Chamber of Commerce.

Mr. Chau speaks fluent English, Cantonese, and Mandarin.

China CNR Corporation Limited’s US$26 Billion Merger with CSR Corporation Limited.
Represented China CNR Corporation Limited in its US$26 billion merger with CSR Corporation Limited. The merger is the first merger of two companies listed in both Hong Kong and Shanghai. (2015)
Evergrande Real Estate Group’s US$600 Million Top-up Placement.
Represented CLSA, Credit Suisse, Haitong International, and Jefferies as placing agents in Guangzhou-based Evergrande Real Estate Group’s US$600 million top-up placement. (2015)
Gree’s US$100 Million Cornerstone Investment in Red Star Macalline Group Corporation Ltd.
Represented Hong Kong Gree Electric Appliances Sales Limited in relation to its US$100 million cornerstone investment in Red Star Macalline Group Corporation Ltd.’s IPO on the Hong Kong Stock Exchange. (2015)
Gree’s US$200 Million Cornerstone Investment in Dailian Wanda Commercial Properties Co., Ltd.
Represented Hong Kong Gree Electric Appliances Sales Limited in relation to its US$200 million cornerstone investment in Dailian Wanda Commercial Properties Co., Ltd.’s IPO on the Hong Kong Stock Exchange. Dailian Wanda Commercial Properties Co., Ltd.’s IPO was one of the most high profile capital markets transactions in 2014. (2014)
Genscript Biotech Corporation HK$524million IPO.
Represented the Sole Sponsor, Haitong International Capital Limited, and the Underwriters, Haitong International Securities Company Limited, J.P. Morgan Securities (Asia Pacific) Limited, J.P. Morgan Securities plc, KGI Capital Asia Limited, and RHB Securities Hong Kong Limited, in relation to life science research and application services company Genscript Biotech Corporation’s HK$524million IPO on the Hong Kong Stock Exchange.
China VAST Industrial Urban Development Company Limited.
Represented China VAST Industrial Urban Development Company Limited in relation to its US$132 million IPO on the Hong Kong Stock Exchange. China VAST Industrial Urban Development Company Limited is a leading service provider in the planning, development and operation of large-scale industrial towns in China, with focuses on development of large-scale industrial towns with land area of 10 million square metres or more. (2014)
Sinopharm's US$515 Million New H-Share Placement.
Represented China International Capital Corp (CICC), UBS, and Morgan Stanley as placing agents for Sinopharm Group Co. Ltd.’s New H-Share placement raising HK$4 billion (approximately US$515 million). (2013)
China CITIC Bank Corporation Limited's US$4 Billion A+H Share Rights Issue.
Represented China International Capital Corp (CICC) and CITIC Securities as joint underwriters in the US$4 billion A+H Share rights issue of China CITIC Bank Corporation Limited. China CITIC Bank Corporation Limited is China\s seventh-largest lender in terms of total assets. (2011)
Sinopharm's US$440 Million H-Share Placement.
Represented China International Capital Corporation, UBS AG, and Morgan Stanley & Co. International plc. (as placing agents) on the US$442.5 million Sinopharm Group Co. Ltd., the largest distributor of pharmaceutical and healthcare products in China. (2011)
Sino-Ocean Land Holdings Limited’s US$684 Million Share Placing.
Represented BOCI Asia Limited and UBS AG (as placing agents) in the US$684 million placing of shares of Sino-Ocean Land Holdings Limited by its shareholder COSCO International Holdings Limited. (2010)
HL Technology Group Limited's US$65 Million IPO.
Represented HL Technology Group Limited in its US$65 million initial public offering on the Hong Kong Stock Exchange.  Piper Jaffray Asia Securities Limited was the sole lead manager of the transaction. (2010)
US$35 Million Investment in ShiFang Holding Limited.
Represented Templeton Strategic Emerging Market Fund III, LDC, Sinochem Europe Capital Corporation Ltd., CCB International Asset Management Limited and New World Strategic Investment Limited in their US$35 million investment in ShiFang Holding Limited, an electronic and printed media content provider in Fujian (2010)
China ITS (Holdings) Co., Ltd.'s Pre-IPO Financing.
Represented China ITS (Holdings) Co., Ltd., a leading traffic engineering and intelligent traffic system company in Beijing, in its various rounds of pre-IPO financing, introducing Baring, Investor AB, China Merchant, Temasek Capital (Private) Limited, GE Capital, Intel Capital, Mizuho, and NWS Holdings as shareholders (2007-2010)
Sinopharm US$1.1 billion IPO.
Represented the group of underwriters, which included China International Capital Corporation, UBS AG, Morgan Stanley Asia Limited, Deutsche Bank AG, and Citigroup Global Markets Asia Limited, in the US$1.1 billion initial public offering of Sinopharm Ground Company Limited in Hong Kong. Sinopharm is China's largest distributor of pharmaceuticals and is managed by state-owned China National Pharmaceutical Group. The IPO was awarded "Best IPO of the Year" by FinanceAsia and named as "Best Equity Deal" on IFR Asia's 2009 Roll of Honour. (2009)
China South City’s US$400 Million IPO.
Represented the group of underwriters, which included Merrill Lynch Far East Limited and BOCI Asia Limited in the US$400 million IPO and listing of shares of China South City Holdings Limited, a leading developer and operator of large-scale logistics and trade centers  in China on the Hong Kong Stock Exchange (2009)
China Zhongwang Holdings US$1,380 million IPO.
Represented the group of underwriters, which included CITIC Securities Corporate Finance (HK) Limited, UBS AG, J.P. Morgan Securities Ltd., Macquarie Capital Securities Limited in the US$1,380 million IPO and listing of shares of China Zhongwang Holdings Limited on the Hong Kong Stock Exchange (2009)
Renhe Commercial’s US$435 million IPO.
Represented the group of underwriters, which included BOCI Asia Limited, The Hongkong and Shanghai Banking Corporation Limited, Morgan Stanley Asia Limited and UBS AG in the US$435 million IPO and listing of shares of Renhe Commercial Holdings Commercial Limited, a leading underground shopping mall developer and operator in China on the Hong Kong Stock Exchange (2008)
Zhejiang Glass Company, Limited’s HK$388 million placing of H shares
Represented Cazenove Asia Limited (as placing agent) in the HK$388 million placing of H shares of Zhejiang Glass Company, Limited (representing 8.9% of the issued share capital of Zhejiang Glass Company, Limited) (2008)
Maoye International Holdings Limited $343 million IPO.
Represented Maoye International Holdings Limited, a leading department store operator, in its US$343 million Hong Kong Stock Exchange initial public offering (2008)
Kingsoft Corporation Limited’s US$115 million IPO.
Represented Kingsoft Corporation Limited, a leading China-based software developer, distributor, and service provider in its US$115 million IPO on the Hong Kong Stock Exchange (2007)
China Resources Power Company Limited’s US$626.4 million top-up share placement.
Represented China Resources Power Company Limited in its US$626.4 million top-up share placement that raised approximately (HK$4.6 billion) of 200 million shares (with Morgan Stanley & Co. International Plc and Citigroup Global Markets Asia Limited as joint placing agents) (2007)

Charles Chau was recommended for Equity Capital Markets and Corporate (including M&A) in Hong Kong by Legal 500 Asia Pacific 2017. He was also ranked as a leading individual in Hong Kong for M&A and Equity Capital Markets by IFLR1000 2017.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2017 Morrison & Foerster LLP. All rights reserved.